Von Willebrand Factor (VWF) Archives

FDA Approves Prophylactic Treatment with VONVENDI for Adult Patients Living with Severe Type 3 von Willebrand Disease

Bleeding Disorders, Blood proteins, Inherited Disorders, Takeda, Therapeutics, von Willebrand Disease (VWD), Von Willebrand Factor (VWF)

The U.S. Food and Drug Administration approved Takeda Pharmaceutical Company Limited’s Vonvendi [von Willebrand factor (Recombinant)] for routine prophylaxis to reduce the frequency of bleeding episodes in patients with severe Type 3 von Willebrand disease (VWD) receiving on-demand therapy.

January 31, 2022/by Business Wire

FDA approves Sanofi’s Cablivi for aTTP

Acquired Thrombotic Thrombocytopenic Purpura (aTTP), Approvals, Blood Disorders, FDA, FDA/Regulatory, Immunosuppression, Nanobodies, Von Willebrand Factor (VWF)

The U.S. FDA approved Cablivi in combination with plasma exchange and immunosuppression for treating acquired thrombotic thrombocytopenic purpura (aTTP) in adults.

February 6, 2019/by GlobeNewswire